lobbying_activities: 2182222
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2182222 | 3a35f6ab-dcc9-499f-80ec-c9909ba942e2 | Q3 | WAXMAN STRATEGIES | 401103693 | 340B HEALTH | 2018 | third_quarter | PHA | Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 | HOUSE OF REPRESENTATIVES,SENATE | 18750 | 0 | 0 | 2018-10-11T09:00:57.097000-04:00 |